Lessons learned from COVID-19 pandemic : outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients
We investigated the outcomes after Coronavirus disease 2019 (COVID) in hematopoietic cell transplant (HCT) or chimeric antigen receptor-T cell (CART) therapy recipients in a single-centre study including all (n = 261)HCT/CART recipients (allogeneic-HCT 49%, autologous-HCT 40%, CART 11%). The median age was 60 (22-80) years. COVID severity was mild (74%), moderate (11%), and severe/critical (16%) with a mortality rate of 7% and a median duration of infection of 5.7 weeks. Significant predictors of COVID severe disease or mortality included concurrent infection (HR 14.9, 95% CI 2.2-5.6) and immunosuppressive therapy (OR 4.8, 95% CI 1.2-3.4).HCT/CART recipients have a higher risk of mortality with COVID and warrant vigilant interventions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Leukemia & lymphoma - 64(2023), 12 vom: 15. Dez., Seite 1981-1991 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al-Ramahi, Joe S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10428194.2023.2243355 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360743102 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360743102 | ||
| 003 | DE-627 | ||
| 005 | 20240301232014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2023.2243355 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM360743102 | ||
| 035 | |a (NLM)37574842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al-Ramahi, Joe S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lessons learned from COVID-19 pandemic |b outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We investigated the outcomes after Coronavirus disease 2019 (COVID) in hematopoietic cell transplant (HCT) or chimeric antigen receptor-T cell (CART) therapy recipients in a single-centre study including all (n = 261)HCT/CART recipients (allogeneic-HCT 49%, autologous-HCT 40%, CART 11%). The median age was 60 (22-80) years. COVID severity was mild (74%), moderate (11%), and severe/critical (16%) with a mortality rate of 7% and a median duration of infection of 5.7 weeks. Significant predictors of COVID severe disease or mortality included concurrent infection (HR 14.9, 95% CI 2.2-5.6) and immunosuppressive therapy (OR 4.8, 95% CI 1.2-3.4).HCT/CART recipients have a higher risk of mortality with COVID and warrant vigilant interventions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cellular | |
| 650 | 4 | |a hematologic malignancies | |
| 650 | 4 | |a hematopoietic stem cell transplant | |
| 650 | 4 | |a infectious complications | |
| 650 | 4 | |a marrow and stem cell transplantation | |
| 650 | 4 | |a therapy | |
| 700 | 1 | |a Shahzad, Moazzam |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a DeJarnette, Shaun |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhary, Sibgha Gull |e verfasserin |4 aut | |
| 700 | 1 | |a Lutfi, Forat |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Nausheen |e verfasserin |4 aut | |
| 700 | 1 | |a Balusu, Ramesh |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Rajat |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelhakim, Haitham |e verfasserin |4 aut | |
| 700 | 1 | |a Shune, Leyla |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Anurag K |e verfasserin |4 aut | |
| 700 | 1 | |a Abhyankar, Sunil H |e verfasserin |4 aut | |
| 700 | 1 | |a McGuirk, Joseph P |e verfasserin |4 aut | |
| 700 | 1 | |a Mushtaq, Muhammad Umair |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia & lymphoma |d 1989 |g 64(2023), 12 vom: 15. Dez., Seite 1981-1991 |w (DE-627)NLM012624047 |x 1029-2403 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2023 |g number:12 |g day:15 |g month:12 |g pages:1981-1991 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2023.2243355 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2023 |e 12 |b 15 |c 12 |h 1981-1991 | ||